MacroGenics, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.97
- 52-Week Range
- $1.32 – $5.08
- Market Cap
- $126.54M
- P/E (TTM)
- —
- EPS (TTM)
- -2.30
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 5.03
- PEG Ratio
- —
- Return on Equity
- -284.54%
- Return on Assets
- -14.58%
- Gross Margin
- -23.82%
- Operating Margin
- -48.83%
- Profit Margin
- -36.57%
- Current Ratio
- 2.75
- Debt/Equity
- 1.39
- Total Debt
- $34.86M
- Free Cash Flow
- $99.19M
- Revenue Growth
- -64.80%
- Earnings Growth
- —
- Enterprise Value
- $-126.28M
Market Snapshot
About
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies. The company develops innovative antibody-based therapeutics using proprietary technology platforms to create treatments for cancer and autoimmune diseases, with multiple product candidates in clinical development.